DAVA Oncology
@DAVAOnc
DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.
おすすめツイート
🚀 Only 1 week to go! Excited to announce the agenda for the 8th DAVA Summit on Genitourinary Malignancies! 🌟 #DAVAGU will cover the latest data and emerging strategies in bladder, kidney and prostate cancer. Register for the free virtual program- forms.office.com/r/DtH8RJh47a
Meet our chairs for the Bermuda GU Summit! Learn from leading experts in the field as they share their insights and expertise. Check out the website to view the confirmed faculty! dava.link/BermudaGU25 #DAVAGU
Virtual registration for the 8th DAVA Summit on Genitourinary Malignancies is now open! ✨Register now and don't miss this incredible opportunity to learn, connect, and be inspired. forms.office.com/r/DtH8RJh47a #DAVAGU
Announcing the 8th Summit on Genitourinary Malignancies by DAVA Oncology! Join us this November to explore the latest data and emerging strategies in bladder, kidney & prostate cancer. Keep your 👀 on our socials for a sneak peek. Check out the website! dava.link/BermudaGU25
@DAVAOnc Academia without friends at meetings is like Bermuda without sunshine Why would you want it? 🌞 Grateful for all I’ve learned from these friends. #DAVAGI
Day 3 of @DAVAOnc GI malignancies summit is in the books. Had to snap a pic with the maestro @vinaykjain17 who makes this and many other great events happen in the oncology space! #livertwitter
Nice to see friends, mentors and industry partners to embark on more trials in PDAC. @utswcancer
Can HDAC inhibitors expand treatment options in PDAC? Early data: ivaltinostat + chemo (ORR 25%, mOS 11.7 mo) and entinostat + IO (ORR 11%). Discussed by @Salthecancerguy @UTSW #DAVAGI
Delighted to be back in Bermuda 🏝️ for @DAVAOnc GI Malignancies Global Summit - sharing updates on new vaccine and immuno-oncology strategies for patients with colorectal and pancreatic cancer 🌍🎗️🧬
Excited to have these trials available for our patients! @AdventHealthCFL @drzakoncology
ACTION & RESTORE trials take exercise beyond survivorship, testing whether aerobic training during adjuvant therapy influences both clinical outcomes & biological remodeling in colon cancer. @Dr_M_Tejani @AdventHealthCFL #DAVAGI
Mayo Clinic, MD Anderson, Stanford and U Miami representing NETs at #DavaOnc Day 3 of 4 done!! @DAVAOnc
Ending @DAVAOnc GI malignancies on a high note with a session on liver metastases and locally advanced #HCC moderated by @docamitgs @sepideh_gholami #livertwitter
The very last @DAVAOnc summit on GI malignancies is underway. Congratulations to @vinaykjain17 and the DAVA team for another tour de force. Over 170 talks in 4 days. Lots of fruitful interactions and learning! #DAVAGI
The 2025 DAVA Bermuda GI Summit has successfully concluded. We deeply appreciate the contributions of all attendees for their expert knowledge, thoughtful discussions, and active participation. #DAVAGI
Gastric cancer with peritoneal metastases (20–45% cases; OS 3–4 mountreated) remains difficult to treat. @Jenny_J_Li @MDAndersonNews reviewed IP chemo approaches (HIPEC, NIPEC, PIPAC); early trials show promise but remain investigational. #DAVAGI
Starting Now: Peritoneal Mets and Appendiceal Cancer Moderated by: @vinaykjain17 #DAVAGI
EpCAM is overexpressed in GI cancers. Dr. Andrew Coveler @FredHutch highlighted KK-2269 & BA3182. KK-2269 (EpCAM–CD40) showed preclinical synergy w/ docetaxel; trials ongoing. BA3182 (EpCAM–CD3 CAB, n=39) showed manageable safety & favorable SC PK vs IV. #DAVAGI
Starting Now: Antibody-drug Conjugates Moderated by: @kanwal_raghav @MDAndersonnews #DAVAGI
CCNE1 amplification (~4–10% of esophagogastric cancers) is linked to CIN, poor prognosis & resistance. At #DAVAGI, @RyanMoyMDPhD @columbiacancer discussed PKMYT1 inhibition with lunresertib(RP-6306), showing preclinical activity & synergy with anti-PD1.
At #DAVAGI, @rutikamehtaMD presented utility of ctDNA MRD testing in gastric/upper GI cancers: persistence/rise predicts recurrence. ctDNA detects recurrence upto 3.5 mo before imaging. In surveillance, positivity→81% recurrence, mRFS 6 mo; negativity→13.5% recurrence, NR mRFS.
Starting Now: Emerging Approaches to Increase IO Efficacy in GE Junction Tumors Moderated by: Dr. Manish Shah @WeillCornell #DAVAGI
United States トレンド
- 1. INCOGNITO 4,353 posts
- 2. Cynthia 86.9K posts
- 3. #WorldKindnessDay 12.8K posts
- 4. #NXXT_EarningReport N/A
- 5. Katie Couric 3,437 posts
- 6. Massie 87.9K posts
- 7. CarPlay 2,059 posts
- 8. Larry Brooks 2,729 posts
- 9. Encyclopedia Galactica 4,436 posts
- 10. GRABFOOD LOVES LINGORM 973K posts
- 11. #LoveDesignEP7 113K posts
- 12. Bonhoeffer 2,129 posts
- 13. Tommy James N/A
- 14. RIN AOKBAB BEGIN AGAIN 111K posts
- 15. $NXXT 1,422 posts
- 16. #thursdayvibes 3,917 posts
- 17. Black Mirror 3,231 posts
- 18. Bongino 8,509 posts
- 19. Good Thursday 38.7K posts
- 20. Michael Burry 11.8K posts
おすすめツイート
-
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein -
Krina Patel
@DrKrinaPatel -
SWOG Cancer Research Network
@SWOG -
Suresh S. Ramalingam, MD, FASCO
@RamalingamMD -
Eric J. Small, MD, FASCO
@ASCOPres -
Jason Westin, MD FACP FASCO
@Lymphoma_Doc -
Vishal Navani, MD
@navstruck -
Julie Vose
@DrJulieVose -
Tycel Phillips
@LymphClinician -
Ticiana Batista (Leal)
@LealTiciana -
Binay Shah, MD, MHA
@binayshah -
Danilov Lab
@DanilovLab -
Andrew M. Evens, DO, MBA, MSc
@DrAEvens -
Skip Burris, MD
@BurrisSkip -
GRACE
@cancerGRACE
Something went wrong.
Something went wrong.